causal

CAR T-Cell Logistics Limit Scalability

CAR T-cell therapy requires extracting a patient's immune cells, flying them to a manufacturing site, gene-editing them, and flying them back within a short window because cell viability declines and the patients are gravely ill, which makes the process very hard to scale beyond niche use cases.

causalpending

Speaker

Alex

Evidence Quote

“There's a lot of kinks in those processes that need to be ironed out before these technologies become scalable beyond these niche use cases.”

Source

Alex Telford - Unlocking Innovation in Pharma - [Invest Like the Best, EP.360]— Invest Like the Best
Created: 11/14/2026, 6:42:06 AM

Your notes

Loading notes...